Toxicity-dependent feasibility bounds for the escalation with overdose control approach in phase I cancer trials. (2017)
Attributed to:
Adaptive Clinical Trials
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/sim.7280
PubMed Identifier: 28295513
Publication URI: http://europepmc.org/abstract/MED/28295513
Type: Journal Article/Review
Volume: 36
Parent Publication: Statistics in medicine
Issue: 16
ISSN: 0277-6715